Franck Touret
@franckdrtourte.bsky.social
PhD in virology
Associate professeur in @UVE lab (Marseille, France). Holder of the new chair: Antiviral strategies for emergence in the south @IRD
Head of the PCVMT platform ( sub-entity of MaSC) dedicated to antiviral screening with replicating viruses.
Associate professeur in @UVE lab (Marseille, France). Holder of the new chair: Antiviral strategies for emergence in the south @IRD
Head of the PCVMT platform ( sub-entity of MaSC) dedicated to antiviral screening with replicating viruses.
Yes on suit ça de près aussi 😁
May 20, 2025 at 8:08 PM
Yes on suit ça de près aussi 😁
While not a replacement for standard antiviral screening, this 3D model offers valuable insights into viral replication, pathogenicity, and host-pathogen interactions.
May 12, 2025 at 11:52 AM
While not a replacement for standard antiviral screening, this 3D model offers valuable insights into viral replication, pathogenicity, and host-pathogen interactions.
Our research findings:
RVFV and PIRV replicated in the liver spheroids; AHFV and YFV did not.
Broad-spectrum antivirals (favipiravir, nitazoxanide, ribavirin, galidesivir) showed activity, though higher doses were often needed versus traditional 2D models.
RVFV and PIRV replicated in the liver spheroids; AHFV and YFV did not.
Broad-spectrum antivirals (favipiravir, nitazoxanide, ribavirin, galidesivir) showed activity, though higher doses were often needed versus traditional 2D models.
May 12, 2025 at 11:52 AM
Our research findings:
RVFV and PIRV replicated in the liver spheroids; AHFV and YFV did not.
Broad-spectrum antivirals (favipiravir, nitazoxanide, ribavirin, galidesivir) showed activity, though higher doses were often needed versus traditional 2D models.
RVFV and PIRV replicated in the liver spheroids; AHFV and YFV did not.
Broad-spectrum antivirals (favipiravir, nitazoxanide, ribavirin, galidesivir) showed activity, though higher doses were often needed versus traditional 2D models.
Haemorrhagic fever viruses remain a major global health threat—highly lethal, with limited therapeutic options. In our recent study, we explored a 3D human liver spheroid model to evaluate its potential for antiviral assessment against 4 BSL-3 viruses: AHFV, YFV, PIRV, RVFV.
May 12, 2025 at 11:52 AM
Haemorrhagic fever viruses remain a major global health threat—highly lethal, with limited therapeutic options. In our recent study, we explored a 3D human liver spheroid model to evaluate its potential for antiviral assessment against 4 BSL-3 viruses: AHFV, YFV, PIRV, RVFV.
On a des antiviraux efficaces: paxlovid ( Nirmatrelvir) et xocova ( ensitrelvir) on sait comment faire un vaccin ou des anticorps thérapeutiques rapidement.
On est entouré de virus à la capacité zoonotique et celui là se rajoute juste à la longue liste mais tkt a l UVE on est là pour ça 😉
On est entouré de virus à la capacité zoonotique et celui là se rajoute juste à la longue liste mais tkt a l UVE on est là pour ça 😉
February 24, 2025 at 2:00 PM
On a des antiviraux efficaces: paxlovid ( Nirmatrelvir) et xocova ( ensitrelvir) on sait comment faire un vaccin ou des anticorps thérapeutiques rapidement.
On est entouré de virus à la capacité zoonotique et celui là se rajoute juste à la longue liste mais tkt a l UVE on est là pour ça 😉
On est entouré de virus à la capacité zoonotique et celui là se rajoute juste à la longue liste mais tkt a l UVE on est là pour ça 😉
Oui c’est uniquement l’entrée mais d’autre facteurs rentrent en ligne de compte pour un changement d’hôte et une zoonose( par exemple la capacité du virus à échapper à la réponse immune). De plus avec le recul un coronavirus est moins inquiétant que d’autres familles virales 1/2
February 24, 2025 at 1:53 PM
Oui c’est uniquement l’entrée mais d’autre facteurs rentrent en ligne de compte pour un changement d’hôte et une zoonose( par exemple la capacité du virus à échapper à la réponse immune). De plus avec le recul un coronavirus est moins inquiétant que d’autres familles virales 1/2
Moreover, pharmacokinetic modeling suggests promising druggability for these compounds.
These results position OM1260 and HR-568 as strong candidates for further development, potentially paving the way for the first curative treatments for enteroviral infections.
These results position OM1260 and HR-568 as strong candidates for further development, potentially paving the way for the first curative treatments for enteroviral infections.
February 14, 2025 at 5:22 PM
Moreover, pharmacokinetic modeling suggests promising druggability for these compounds.
These results position OM1260 and HR-568 as strong candidates for further development, potentially paving the way for the first curative treatments for enteroviral infections.
These results position OM1260 and HR-568 as strong candidates for further development, potentially paving the way for the first curative treatments for enteroviral infections.
Docking studies provided insights into their structure-activity relationships, while time-of-drug addition assays revealed that these inhibitors act early in the viral replication cycle.
February 14, 2025 at 5:21 PM
Docking studies provided insights into their structure-activity relationships, while time-of-drug addition assays revealed that these inhibitors act early in the viral replication cycle.
This led to the discovery of two promising broad-spectrum inhibitors, OM1260 and HR-568.
Both inhibitors show micromolar activity against multiple enterovirus types (EV-A71, E30, and CVA24), with EC50 values ranging from 0.4 μM to 4.38 μM, depending on the virus strain and cell line.
Both inhibitors show micromolar activity against multiple enterovirus types (EV-A71, E30, and CVA24), with EC50 values ranging from 0.4 μM to 4.38 μM, depending on the virus strain and cell line.
February 14, 2025 at 5:21 PM
This led to the discovery of two promising broad-spectrum inhibitors, OM1260 and HR-568.
Both inhibitors show micromolar activity against multiple enterovirus types (EV-A71, E30, and CVA24), with EC50 values ranging from 0.4 μM to 4.38 μM, depending on the virus strain and cell line.
Both inhibitors show micromolar activity against multiple enterovirus types (EV-A71, E30, and CVA24), with EC50 values ranging from 0.4 μM to 4.38 μM, depending on the virus strain and cell line.
Our consortium has made an exciting step forward in the fight against these viruses. After developing initial EV-A71 inhibitors, we optimized their structure through iterative chemical modifications to enhance their activity and broaden their spectrum.
February 14, 2025 at 5:21 PM
Our consortium has made an exciting step forward in the fight against these viruses. After developing initial EV-A71 inhibitors, we optimized their structure through iterative chemical modifications to enhance their activity and broaden their spectrum.
Despite their significant impact, there are currently no commercial curative treatments available.
February 14, 2025 at 5:21 PM
Despite their significant impact, there are currently no commercial curative treatments available.
Read more about our findings in the preprint! 📖
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Assessing Human Liver Spheroids as a Model for Antiviral Drug Evaluation Against BSL-3 Haemorrhagic Fever viruses
Haemorrhagic fever viruses (HFVs) cause highly lethal syndromes with limited therapeutic options. Increasingly, 3D cell culture models are becoming an important tool in the field of virology. Since th...
www.biorxiv.org
January 30, 2025 at 7:48 AM
Read more about our findings in the preprint! 📖
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Our research underscores the growing importance of advanced 3D models in virology and drug development. This tool could help accelerate the identification of new therapies for HFVs and improve our understanding of their mechanisms.
January 30, 2025 at 7:48 AM
Our research underscores the growing importance of advanced 3D models in virology and drug development. This tool could help accelerate the identification of new therapies for HFVs and improve our understanding of their mechanisms.
While this model offers valuable insights, it’s not a replacement for standard selection steps in antiviral drug development but could play a key role in understanding viral pathogenicity and host-pathogen interactions.
January 30, 2025 at 7:47 AM
While this model offers valuable insights, it’s not a replacement for standard selection steps in antiviral drug development but could play a key role in understanding viral pathogenicity and host-pathogen interactions.
Key findings :
RVFV and PIRV were able to replicate in the spheroids, while the orthoflaviviruses did not show replication.
Antiviral compounds like favipiravir, nitazoxanide, ribavirin, and galidesivir demonstrated activity, though higher doses were required in 3D models compared to 2D cultures.
RVFV and PIRV were able to replicate in the spheroids, while the orthoflaviviruses did not show replication.
Antiviral compounds like favipiravir, nitazoxanide, ribavirin, and galidesivir demonstrated activity, though higher doses were required in 3D models compared to 2D cultures.
January 30, 2025 at 7:47 AM
Key findings :
RVFV and PIRV were able to replicate in the spheroids, while the orthoflaviviruses did not show replication.
Antiviral compounds like favipiravir, nitazoxanide, ribavirin, and galidesivir demonstrated activity, though higher doses were required in 3D models compared to 2D cultures.
RVFV and PIRV were able to replicate in the spheroids, while the orthoflaviviruses did not show replication.
Antiviral compounds like favipiravir, nitazoxanide, ribavirin, and galidesivir demonstrated activity, though higher doses were required in 3D models compared to 2D cultures.
Our latest study explores the use of a 96-well liver spheroid model composed of human primary cells to assess the antiviral activity of key compounds against four BSL-3 HFVs: Alkhumra haemorrhagic fever virus (AHFV), yellow fever virus (YFV), Pirital virus (PIRV), and Rift Valley fever virus (RVFV).
January 30, 2025 at 7:46 AM
Our latest study explores the use of a 96-well liver spheroid model composed of human primary cells to assess the antiviral activity of key compounds against four BSL-3 HFVs: Alkhumra haemorrhagic fever virus (AHFV), yellow fever virus (YFV), Pirital virus (PIRV), and Rift Valley fever virus (RVFV).
From Rogue virologist
January 9, 2025 at 7:47 PM
From Rogue virologist